Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Pentazocine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 10/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 4/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | EBP | Q15125 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentazocine SCHEMBL2493 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL2492 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| Rel-Pentazocine SCHEMBL135685 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL16220021 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL16144643 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL18672553 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL4376337 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL680675 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL22865258 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| Pentazocine SCHEMBL29611805 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269230-A1 | CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPY | MEDIZINISCHE UNIVERSITAT WIEN (AT) | 2024-08-15 | — | — | US | claimed |
| CN-115697371-A | Macrocyclic oligopeptides in combination with kappa opioid receptor ligands for MS therapy | 维也纳医科大学 | 2023-02-03 | — | — | CN | claimed |
| EP-4121085-A1 | CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPY | Medizinische Universität Wien (AT) | 2023-01-25 | — | — | EP | claimed |
| US-20240366513-A1 | Methods For Administering Weight Loss Medications | NALPROPION PHARMACEUTICALS LLC (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240269230-A1 | CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPY | MEDIZINISCHE UNIVERSITAT WIEN (AT) | 2024-08-15 | — | — | US | disclosed |
| US-12048769-B2 | Methods for administering weight loss medications | NALPROPION PHARMACEUTICALS LLC (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230301922-A1 | Layered Pharmaceutical Formulations | NALPROPION PHARMACEUTICALS LLC (US) | 2023-09-28 | — | — | US | disclosed |
| CN-115697371-A | Macrocyclic oligopeptides in combination with kappa opioid receptor ligands for MS therapy | 维也纳医科大学 | 2023-02-03 | — | — | CN | disclosed |
| EP-4121085-A1 | CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPY | Medizinische Universität Wien (AT) | 2023-01-25 | — | — | EP | disclosed |